The approval of Osmolex ER was based on bioavailability studies comparing Osmolex ER to immediate-release amantadine. Osmotica announced that the Food and Drug Administration (FDA) has approved ...
EPSs are serious, debilitating and stigmatizing adverse effects that frequently require additional pharmacotherapy. 3 The two types of EPSs are as follows: early acute EPS, which most often develops ...
Ondansetron is a selective 5-HT3 antagonist with significant antiemetic properties in patients receiving cytotoxic chemotherapy. Patients who had suffered severe vomiting on carboplatin alone (23 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results